Colombian Flourishing Curriculum
NCT07928375, Not applicable, Completed, Universidad del Sinú - Elías Bechara Zainúm
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Colombian Flourishing Curriculum | ClinicalTrials.gov |
| NCT number | NCT07928375 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 1,156 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Universidad del Sinú - Elías Bechara Zainúm | ClinicalTrials.gov |
| Conditions | Wellbeing | ClinicalTrials.gov |
| Interventions | Flourishing curriculum, Regular course | ClinicalTrials.gov |
| First posted | 2026-11-10 | ClinicalTrials.gov |
| Last updated | 2026-11-10 | ClinicalTrials.gov |
Registered outcomes 20
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Overall Flourishing: Flourish Measure | T1 Baseline, T2 End of nine weeks, T3 One-month Follow-up | Use the total score across 10 items of the Flourish measure developed by Tyler VanderWeele. Scale score ranges from 0 to 10. Higher score indicates better outcome. | ClinicalTrials.gov |
| Primary | Happiness and Life Satisfaction: subscale of Flourish Measure | T1 Baseline, T2 End of nine weeks, T3 One-month Follow-up | subscale of the Flourish measure of the the first outcome developed by VanderWeele. Scale score ranges from 0 to 10. Higher score indicates better outcome. | ClinicalTrials.gov |
| Primary | Mental and Physical Health: subscale of Flourish Measure | T1 Baseline, T2 End of nine weeks, T3 One-month Follow-up | subscale of the Flourish measure of the the first outcome developed by VanderWeele. Scale score ranges from 0 to 10. Higher score indicates better outcome. | ClinicalTrials.gov |
| Primary | Meaning and Purpose: subscale of Flourish Measure | T1 Baseline, T2 End of nine weeks, T3 One-month Follow-up | subscale of the Flourish measure of the the first outcome developed by VanderWeele. Scale score ranges from 0 to 10. Higher score indicates better outcome. | ClinicalTrials.gov |
| Primary | Character and Virtue: subscale of Flourish Measure | T1 Baseline, T2 End of nine weeks, T3 One-month Follow-up | subscale of the Flourish measure of the the first outcome developed by VanderWeele. Scale score ranges from 0 to 10. Higher score indicates better outcome. | ClinicalTrials.gov |
| Primary | Close Social Relationships: subscale of Flourish Measure | T1 Baseline, T2 End of nine weeks, T3 One-month Follow-up | subscale of the Flourish measure of the the first outcome developed by VanderWeele. Scale score ranges from 0 to 10. Higher score indicates better outcome. | ClinicalTrials.gov |
| Primary | Depression symptoms: Patient Health Questionnaire-9(PHQ-9) | T1 Baseline, T2 End of nine weeks, T3 One-month Follow-up | Scale score ranges from 0 to 3. Higher score indicates higher depression. | ClinicalTrials.gov |
| Primary | Anxiety Symptoms: Generalized Anxiety Disorder-7 (GAD-7) | T1 Baseline, T2 End of nine weeks, T3 One-month Follow-up | Scale score ranges from 0 to 3. Higher score indicates higher symptom. | ClinicalTrials.gov |
| Primary | The Short Stress Overload Scale | T1 Baseline, T2 End of nine weeks, T3 One-month Follow-up | Scale score ranges from 1 to 5. Higher score indicates higher stress. | ClinicalTrials.gov |
| Primary | Coherence: subscale of the Three Dimensional Meaning in Life Scale (3DM) | T1 Baseline, T2 End of nine weeks, T3 One-month Follow-up | Scale score ranges from 1 to 7. Higher score indicates higher meaning. | ClinicalTrials.gov |
| Primary | Purpose: subscale of the Three Dimensional Meaning in Life Scale (3DM) | T1 Baseline, T2 End of nine weeks, T3 One-month Follow-up | Scale score ranges from 1 to 7. Higher score indicates higher meaning. | ClinicalTrials.gov |
| Primary | Significance: subscale of the Three Dimensional Meaning in Life Scale (3DM) | T1 Baseline, T2 End of nine weeks, T3 One-month Follow-up | Scale score ranges from 1 to 7. Higher score indicates higher meaning. | ClinicalTrials.gov |
| Primary | Trait Forgivingness Scale | T1 Baseline, T2 End of nine weeks, T3 One-month Follow-up | Scale score ranges from 1 to 5. Higher score indicates higher forgiveness. | ClinicalTrials.gov |
| Primary | Trait Humility: subscael of Relational Humility Scale | T1 Baseline, T2 End of nine weeks, T3 One-month Follow-up | Scale score ranges from 1 to 5. Higher score indicates higher humility. | ClinicalTrials.gov |
| Primary | Cognitive and Affective Mindfulness Scale-Revised (CAMS-R) | T1 Baseline, T2 End of nine weeks, T3 One-month Follow-up | Scale score ranges from 1 to 4. Higher score indicates higher mindfulness. | ClinicalTrials.gov |
| Primary | Brief Self-Control Scale | T1 Baseline, T2 End of nine weeks, T3 One-month Follow-up | Scale score ranges from 1 to 5. Higher score indicates higher self-control | ClinicalTrials.gov |
| Primary | Brief Resilience Scale | T1 Baseline, T2 End of nine weeks, T3 One-month Follow-up | Scale score ranges from 1 to 5. Higher score indicates higher resilience. | ClinicalTrials.gov |
| Primary | Authentic Leadership Inventory (ALI) | T1 Baseline, T2 End of nine weeks, T3 One-month Follow-up | Scale score ranges from 1 to 5. Higher score indicates higher level of leadership. | ClinicalTrials.gov |
| Primary | Loneliness: NIH Toolbox Adult Social Relationship Scales | T1 Baseline, T2 End of nine weeks, T3 One-month Follow-up | Scale score ranges from 1 to 5. Higher score indicates higher level of loneliness | ClinicalTrials.gov |
| Primary | Transcendent Spirituality: subscale of Trait Sources of Spirituality Scale | T1 Baseline, T2 End of nine weeks, T3 One-month Follow-up | Scale score ranges from 1 to 5. Higher score indicates higher level of spirituality | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)